Clinical impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in living donor liver transplantation for advanced hepatocellular Carcinoma

Transplantation

Volumn 99, Issue 10, 2015, Pages 2142-2149

  Lee, Seung Duk ^a   Kim, Seong Hoon ^a   Kim, Seok Ki ^a   Kim, Young Kyu ^b   Park, Sang Jae ^a  

^a National Cancer Center   (South Korea)

^b Jeju National University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; ADVANCED CANCER; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL PREDICTION; SURVIVAL RATE; TUMOR VOLUME; AGED; CARCINOMA, HEPATOCELLULAR; COMPUTER ASSISTED TOMOGRAPHY; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MICROCIRCULATION; MULTIMODAL IMAGING; MULTIVARIATE ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SCINTISCANNING; TREATMENT OUTCOME;

AGED; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MICROCIRCULATION; MIDDLE AGED; MULTIMODAL IMAGING; MULTIVARIATE ANALYSIS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84939574016     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000719     Document Type: Article

References (30)

1. Chen CL, Fan ST, Lee SG, et al. Living-donor liver transplantation: 12 years of experience in Asia. Transplantation. 2003;75(3 Suppl):S6-S11.
2. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693-699.
3. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394-1403.
4. Schwartz M, Roayaie S, Uva P. Treatment of HCC in patients awaiting liver transplantation. Am J Transplant. 2007;7(8):1875-1881.
5. Koschny R, Schmidt J, Ganten TM. Beyond Milan criteria-chances and risks of expanding transplantation criteria for HCC patients with liver cirrhosis. Clin Transplant. 2009;23(Suppl 21):49-60.
6. Toso C, Asthana S, Bigam DL, et al. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology. 2009;49 (3):832-838.
7. Ito T, Takada Y, Ueda M, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl. 2007;13(12):1637-1644.
8. Lee SD, Kim SH, Kim YK, et al. (18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma. Transpl Int. 2013;26(1):50-60.
9. 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med. 2009;50(5):682-687.
10. 18F] fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation. Liver Transpl. 2012;18(1):53-61.
11. Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant. 2008;8(10):1982-1989.
12. Silva MF, Wigg AJ. Current controversies surrounding liver transplantation for hepatocellular carcinoma. J Gastroenterol Hepatol. 2010;25 (7):1217-1226.
13. Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl. 2004;10(4):534-540.
14. 18F-FDG-uptake of hepato-cellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant. 2009;9(3):592-600.
15. Jerusalem G, Hustinx R, Beguin Y, et al. The value of positron emission tomography (PET) imaging in disease staging and therapy assessment. Ann Oncol. 2002;13(Suppl 4):227-234.
16. Kim SH, Cho SY, Park SJ, et al. Learning curve for living-donor liver transplantation in a fledgling cancer center. Transpl Int. 2009;22 (12):1164-1171.
17. Kim SH, Kim YK. Improving outcomes of living-donor right hepatectomy. Br J Surg. 2013;100(4):528-534.
18. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10 (1):35-43.
19. Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis. 2007;25 (4):310-312.
20. Sherman M. The radiological diagnosis of hepatocellular carcinoma. Am J Gastroenterol. 2010;105(3):610-612.
21. Freeman RB, Mithoefer A, Ruthazer R, et al. Optimizing staging for hepatocellular carcinoma before liver transplantation: A retrospective analysis of the UNOS/OPTN database. Liver Transpl. 2006;12 (10):1504-1511.
22. Otto G, Herber S, Heise M, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl. 2006;12 (8):1260-1267.
23. Schwartz M, Dvorchik I, Roayaie S, et al. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol. 2008;49(4):581-588.
24. Shirabe K, Itoh S, Yoshizumi T, et al. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol. 2007;95(3):235-240.
25. Hatano E, Ikai I, Higashi T, et al. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg. 2006;30 (9):1736-1741.
26. Okazumi S, Isono K, Enomoto K, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med. 1992;33(3):333-339.
27. Dierckx R, Maes A, Peeters M, et al. FDG PET for monitoring response to local and locoregional therapy in HCC and liver metastases. Q J Nucl Med Mol Imaging. 2009;53(3):336-342.
28. Yen RF, Chen CY, Cheng MF, et al. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients. Nucl Med Commun. 2010;31(7):637-645.
29. 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepa-tocellular carcinoma in posttransplant patients. Liver Transpl. 2010;16 (6):767-772.
30. Pawlik TM, Gleisner AL, Anders RA, et al. Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Ann Surg. 2007;245(3):435-442.